Background
==========

It has been estimated that 70% of women have a life-long risk of developing leiomyomas, with symptomatic tumors accounting for a 1/3 of all the hysterectomies preformed annually in the United States alone. Such estimates are even higher among African Americans with leiomyomas that develop earlier, become larger and more symptomatic as compared to other ethnic groups \[[@B1]-[@B3]\]. Since leiomyomas develop during the reproductive years and regress with menopause, ovarian steroids are critical to their growth, however the molecular environment to explain these ethnic differences is unknown.

Various conventional and recent large-scale gene expression-profiling studies have provided valuable information regarding the molecular environment of leiomyomas \[[@B4]-[@B11]\]. Most of these studies were based on comparing leiomyomas with myometrium obtained from different ethnic groups without examining the influence of ethnicity on overall gene expression \[[@B9],[@B10],[@B12]\]. Using tissue microarray a recent immunohistochemistry study has reported the expression of a number of proteins in leiomyomas with some differences in their expression intensities in leiomyomas from African Americans as compared to other ethnic groups \[[@B13]\]. In addition, an increased risk of developing leiomyomas, including among African Americans, has been examined in a number of genetic studies, although in a majority of the cases the evidence of genomic instability is inconsistent \[[@B14]-[@B17]\].

Considering the above information and availability of limited data differentiating leiomyomas microenvironment in African Americans in the present study we combined genomic and proteomic strategies comparing the molecular environment of paired leiomyoma and myometrium from African Americans with Caucasians. Furthermore, from microarray data sets we selected 15 differentially expressed genes from different functional categories rather than levels of their expression and validated their expression using realtime PCR in a microfluidic card format. Additionally, 15 protein spots identified by proteomic were isolated and subjected to tandem mass spectrometry (MS/MS) for identification of their content and verified two of these proteins by Western blotting and immunohistochemistry.

Methods
=======

Portions of leiomyoma and matched myometrium were collected from six women, ranging from 29 to 38 years old who were scheduled to undergo hysterectomy for indications related to symptomatic leiomyomas. Three of the patients were Caucasians and three African Americans. These women were not taking any medication including hormonal therapy for the pervious 3 months prior to surgery and based on their last menstrual period and endometrial histology they were from early-mid secretory phase of the menstrual cycle. The myometrium used in this study was collected from regions distal from leiomyomas. All the leiomyomas were subserosal/intramural and 3 to 4 cm in diameter. These tissues were collected at the University of Florida affiliated Shands Hospital with prior approval from the Institutional Review Board without requiring to obtain informed consent. The tissues were snapped frozen and stored in liquid nitrogen until used.

Microarray and gene expression profiling
----------------------------------------

Small portions of the above tissues were used to isolate total RNA using Trizol (Invitrogen, Carlsbad, CA). RNA quality and yield was analyzed with Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA). RNA amplification was carried out as previously described \[[@B7]\], and following second-strand cDNA synthesis 5 μg of purified cDNA was reverse transcribed using Enzo BioArray high yield RNA transcript labeling kit (Affymetrix, Santa Clara, CA). After purifying the product, 20 μg of cRNA (0.5 μg/μl) was fragmented. The fragment then mixed with 300 μl of hybridization mixture and 200 μl of the mixture was hybridized to human U133A Affymetrix GeneChip which consists of 22,277 oligonucleotide probe sets representing 18,400 transcripts and variants, including 14,500 known genes. The chips were processed after meeting recommended criteria for use of the expression arrays as previously described \[[@B7]\] and according to manufactures protocol.

Microarray data analysis
------------------------

The chips were scanned using Affymetrix Genepix 5000A scanner and the resulting images were assessed using Genepix software with a manual supervision to detect any inaccuracies. The net hybridization values were determined and subjected to global normalization and transformed expression values were subjected to Affymetrix Analysis Suite V 5.0 to remove any probe sets that were flagged as absent on all arrays using default settings. The expression value of the remaining probe sets was then subjected to unsupervised and supervised learning, discrimination analysis, and cross validation as previously described \[[@B7]\]. After variation filtering, the coefficient of variation was calculated for each probe set across all chips, ranked and the expression values of the selected genes were then subjected to statistical analysis in \"R\" programming as previously described \[[@B7]\]. The gene expression values having a statistical significance of p ≤ 0.01 (ANOVA, Turkey test) were selected and subjected to 2-fold cutoff. Hierarchical clustering and TreeView analysis was carried out and the selected genes were subjected to functional annotation and visualization using Database for Annotation, Visualization, and Integrated Discovery \[[@B18]\] software. The integrated GoCharts assigns genes to specific ontology functional categories based on selected classifications.

Low-density microfluidic card and realtime PCR
----------------------------------------------

Total RNA isolated from the same paired leiomyomas and myometrium from African Americans and Caucasians used for microarray analysis was also subjected to realtime PCR using microfluidic cards TaqMan Low Density Arrays (LDAs) assessing the level of expression of 23 selected genes, and the house-keeping gene, G3PDH. These genes were selected based on their functional categories rather than the level of their expression from the list of differentially expressed genes identified in the present and our previous \[[@B6],[@B7],[@B19]\] microarray studies. The products of these 23 genes have been implicated in several biological processes involved in pathogenesis of leiomyoma and other fibrotic disorders. Pre-designed TaqMan probe and primer sets for these genes were selected from the on-line catalogue and were factory-loaded into customized 384-well LDA plates (Applied Biosystem, Foster City, CA). The LDA format was arranged on-line with each array containing two replicates for each 23-target gene and GAPDH. Since these LDAs were used to determine the expression of these genes in several different tissues for establishing the least variable housekeeping gene as standard prior to these experiments we utilized a factory-loaded LDA (384-well plate) specific for 12 housekeeping genes. The results indicated that GAPDH expression displayed the least variation among the reference genes in these tissues as well as the tissues used in the accompanied manuscript \[[@B20]\]. Based on these results we selected GAPDH as a housekeeping gene during the development of the LDA and for normalization of the expression of other target genes on LDA. The exact locations and the sequences of the oligonucleotides used in all assays can be downloaded from the Applied Biosystems website \[[@B21]\] by selecting the Assays IDs. All genes span exonintron boundaries and cover the major transcript forms.

The LDAs were analyzed using the 7900HT system with a TaqMan LDA Upgrade (Applied Biosystems). In brief, 5 μl of single-stranded cDNA at final concentration of 2 μg starting RNA was combined with 45 μl water and 50 μl TaqMan Universal PCR Master Mix. The mixture was injected into selected sample ports and the cards were centrifuged twice for 1 min at 1200 rpm and sealed to prevent well-to-well contamination. Thermal cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, 97°C for 30s and 60°C for 1 min for 40 cycles. In all the experiments total RNA isolated from each sample were assayed in duplicate and one sample was used in all cards to assess inter- and intra-assay variability. Since each LDA card has a unique barcode the Sequence Detection System plate documents stores the information on the plate type, detector, sample/target gene configurations, thermal cycling conditions, data collection, and raw fluorescence data at each cycle. The data obtained from each card was analyzed using the comparative method and following normalization of expression values to GAPDH expression using relative quantity (RQ) and Sequence Detection Software 2.2.1 for automated data analysis according to the manufacturer\'s guidelines \[[@B21]\]. For calculating the RQ of selected mRNA in leiomyomas compared with myometrium, or tissues from African Americans compared to Caucasians, myometrial RNA used in each card was designated as calibrator. To analyze the RQ amounts of selected genes as an effect of ethnicity, Caucasian myometrium was used as calibrators. The Ct value \>35 was selected as cutoff for the absence of gene expression. The expression of 15 of these genes is reported here.

Proteomic: protein isolation and CyDye labeling
-----------------------------------------------

Total protein was isolated from 100 to 300 mg of paired frozen leiomyoma and myometrium from African Americans and Caucasians. The tissues were grinded in liquid nitrogen until fine powder, 5 ml of Trizol reagent and 5 to 15 μl of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) was added and centrifuged at 10,000 × g for 20 min at 4°C. Following phase extraction with chloroform the mixture was centrifuged at 5000 RPM at 4°C for 20 min, the inter- and bottom phases were extracted with 100% ethanol and clarified by centrifugation. The protein was precipitated with isopropanol overnight at -20°C and the pellets were washed twice with ice cold 80% ethanol, air dried and dissolved in 300 μl of CyDye labeling buffer (8 M urea, 2 M thiourea, 4% CHAPS, 20 mM Tris pH 8.5) and centrifuged at 40,000 × g for 30 min. The supernatants were transferred to a clean tube and adjusted to pH of 8.5 and protein concentration was determined using EZQ^®^(Invitrogen). Fifty μg of myometrial and leiomyomas protein mixtures was labeled with 400 pM of Cy3 and Cy5 respectively, for 30 min on ice in dark and the reaction was stopped and quenched with 1 μl of 10 mM Lysin.

Two-dimensional electrophoresis
-------------------------------

For the first dimension, the Cy3- and Cy5-labeled proteins were combined with 450 μg each of unlabeled protein and 100 mM of DTT ampholyte buffer pH 3 to 11, to 0.5% and adjusted the final volume to 400 μl. An 18 cm of pH 3 to 11 immobilized pH gradient (IPG) strip was passively rehydrated with above sample solution overnight in the dark. Isoelectrofocusing (IEF) was carried in IPGphor (Amersham, GE Healthcare Bio-Sciences Corp. Piscataway, NJ) and the proteins co-migrated together was focused at 8000 V at 20°C for 60 kV hr. For the second dimension SDS-PAGE, an 8 to 16% precast Tris Glycine gel (BioRad, CA) was used. Prior to mounting, the IPG strips were reduced and equilibrated in 15 ml of 50 mM Tris-HCl pH 6.8, 6 M Urea, 30% (v/v) glycerol 2% (w/v) SDS 100 mM DTT for 15 min, then was alkylated with 15 ml of 50 mM Tris-HCl pH 6.8 6 M Urea 30% (v/v) glycerol 2% SDS 2.5% idoacetamide for 15 min. 2nd dimension was carried in the dark at 20°C for 4 to 5 hrs at 24 mA/gel. MW markers (New England Biolabs, Beverly, MA) were added to the 2D-PAGE.

Image acquisition and spot quantification
-----------------------------------------

The gels were scanned with Typhoon 9400 Variable Mode Imager (Amersham) and following image acquisition the protein spots were identified, their volumes were determined and analyzed using computer-assisted gel analysis and Progenesis PG220 2D software (Nonlinear Dynamics, Durham, NC). The analysis allows automatic detection and quantification of protein spots as well as resizing, alignment, and matching between different 2D gel images. A database of all protein spots obtained from digital images was created, and integrated intensity of each spot was calculated based on spot area and optical density and expressed as percent volume, namely, spot volume/volumes of all spots resolved in the gel. The comparative program was used to geometrically correct spatial differences and allow comparison between the images. The information from comparison of the image databases was then used to establish an average gel. Each protein spot volume was normalized against the total protein spots volume present in the gel and the fold difference of each protein was calculated for the paired myometrium and leiomyoma sample. The list of protein spots with assigned identification number was prepared and arranged according to the fold difference and the values were statistically analyzed using ANOVA, Turkey test.

Protein identification by mass spectrometric analysis
-----------------------------------------------------

The gels were Coomassie blue stained and the spots of interest were identified and manually excised with a disposable gel puncher and stored in 25% methanol until tyrptic digestion according to a protocol used by Proteomics Core Facility of the Inter-disciplinary Cores for Biomedical Research (ICBR) at the University of Florida. Peptides derived from tryptic digestion were analyzed by reversed-phase HPLC-tandem mass spectrometry on a hybrid quadrupole time-of-flight instrument (QSTAR XL, Applied Biosystems) equipped with a nano-electrospray source. Solvent delivery at 200 nl/min was provided by an integrated capillary HPLC system (Ultimate, LC Packings, Sunnyvale, CA) in which a 30 min gradient from 3% to 50% acetonitrile in 0.1% acetic acid was employed. Each information dependent acquisition (IDA) cycle consisted of a survey scan from m/z 400 to 1500 and three MS/MS scans obtained by collision-induced dissociation of ions that demonstrated the largest signal intensity at a given chromatographic time point. Survey and MS/MS scans were accumulated for 1 and 2 sec, respectively.

Tandem mass spectrometric data were searched against the IPI human protein database using the Mascot search algorithm. Carbamidomethylation of cysteine was included as a fixed modification whereas oxidation of methionine, deamidation of asparagine and glutamine, and pyro-glu formation from N-terminal glutamine or glutamic acid were included as variable modifications. Probability-based MOWSE scores that exceeded the value corresponding to p \< 0.05 were considered for protein identification. After inputting the pI and MW of proteins Swiss-Prot Database was searched by TagIdent software (Swiss Institute of Bioinformatics, Basel, Switzerland) for matching proteins.

Western blot analysis
---------------------

Briefly, small portions of paired leiomyoma and myometrial tissues were homogenized in homogenizing buffer containing protease inhibitor cocktail \[[@B22]\]. The laysets were centrifuged, supernatants protein content was determined and an equal amount of proteins was subjected to SDS-PAGE, transfer by electroblotting and the blots were exposed to polyclonal antibodies generated against 14-3-3β and mimecan (Santa Cruz Biotechnology, Santa Cruz, CA), respectively and monoclonal antibody to β-actin (Sigma) to normalize for protein loading. The blots were exposed to corresponding HRP-conjugated IgG and visualized using enhanced chemiluminesence reagents (Amersham). The band intensity was determined using Kodak gel analysis software (Eastman Kodak, Rochester, New York).

Immunohistochemistry
--------------------

For immunohistochemical localization of 14-3-3β and mimecan, fixed and paraffin embedded leiomyomas and myometrial tissue sections 3 to 5 μm thick were prepared. Following standard procedures, the sections were incubated with polyclonal antibodies at 5 μg of IgG/ml prepared in phosphate buffered saline, pH 7.4 \[[@B22]\]. The sections were than exposed to biotinylated second antibodies and avidin horseradish peroxidase (Vector Laboratories, Burlingame, CA) and chromogenic reaction was developed using 3, 3\'diaminobenzidine and counter sections were counter staining with hemotoxalin as indicated. Tissue sections incubated with normal IgG instead of the primary antibodies, or deletion of the primary antibodies during immunostaining served as controls.

Results
=======

Gene expression profiling of leiomyomas from African Americans and Caucasians
-----------------------------------------------------------------------------

Gene expression values obtained from microarray analysis of paired leiomyoma and myometrium from African Americans and Caucasians were subjected to unsupervised and supervised learning. Based on statistical analysis with p ranking of P ≤ 0.01 we identified 1470 transcripts, or 8% of the genes on the array, as differentially expressed among these tissues regardless of ethnicity. Further analysis based on 2-fold cutoff resulted in identification of 268 genes with 177 genes over-expressed and 91 genes under-expressed in leiomyomas of African Americans as compared to Caucasians (Table [1](#T1){ref-type="table"}; for the complete list of genes see Table 4, Additional file [1](#S1){ref-type="supplementary-material"}). Hierarchical clustering separated these genes into several distinctive clusters (Fig. [1](#F1){ref-type="fig"}) and functional pathway analysis indicated that majority of their products serve as transcriptional, translational and signal transduction mediators, cell cycle regulation, ECM turnover, cell-cell communication and metabolic activities etc.

###### 

Differentially expressed genes in leiomyomas of African Americans as compared to Caucasians

  Gene Bank   Gene Symbol   Probability   Fold Change   Biological Function
  ----------- ------------- ------------- ------------- --------------------------------
  P43115      PTGER3        0.007         3.05          signal transduction
  NM_006549   CAMKK2        0.0004        2.66          signal transduction
  Q92844      TANK          0.00002       2.57          signal transduction
  NM_000267   NF1           0.0004        2.57          signal transduction
  L35253      MAPK14        0.0011        2.51          signal transduction
  Q16825      PTPN21        0.004         2.51          signal transduction
  P04156      PRNP          0.00003       2.33          signal transduction
  P27986      PIK3R1        0.004         2.19          signal transduction
  NM_002835   PTPN12        0.0001        2.18          signal transduction
  P04901      GNB1          0.0002        2.02          signal transduction
  NM_005456   MAPK8IP1      0.006         0.50          signal transduction
  P17612      PRKACA        0.003         0.50          signal transduction
  NM_003331   TYK2          0.001         0.50          signal transduction
  P17010      ZFX           0.0004        3.73          transcription factor
  O00712      NFIB          0.00002       2.56          transcription factor
  NM_002040   GABPA         0.004         2.38          transcription
  U18671      STAT2         0.001         2.20          transcription
  AF040963    MXD4          0.0002        0.50          transcription
  Q9Y6K9      IKBKG         0.004         0.50          transcription
  L41066      NFATc4        0.001         0.48          transcription
  P26196      DDX6          0.008         0.48          RNA processing
  O95997      PTTG1         0.009         0.37          oncogenes/tumor suppressors
  NM_012141   DDX26         0.0009        0.31          tumor suppressor
  P10159      EIF5A         0.0004        2.63          translation
  NM_001969   EIF5          0.0001        2.15          translation
  NM_000141   FGFR2         0.002         12.66         growth factor receptor
  NM_005761   PLXNC1        0.002         3.48          cell receptor
  P36897      TGFBR1        0.006         4.81          growth factor receptor
  D50683      TGFBR2        0.006         3.54          growth factor receptor
  O60462      NRP2          0.002         2.43          cell receptors
  O94816      FZD7          0.004         2.04          cell receptors
  M26062      IL2RB         0.002         0.46          cell receptors
  NM_004883   NRG2          0.007         0.46          cell signaling
  M59040      CD44          0.002         2.70          cell surface antigens
  P07585      DCN           0.007         2.00          cell surface antigens
  P30408      TM4SF1        0.004         2.00          cell surface antigens
  M_002456    MUC1          0.008         0.48          cell surface antigens
  Q9NVA2      FLJ10849      0.002         3.55          cell cycle
  P54826      GAS1          0.001         2.12          cell cycle
  Q14004      CDC2L5        0.0001        2.05          cell cycle
  NM_003644   GAS7          0.005         0.50          cell cycle
  P29466      CASP1         0.008         2.28          apoptosis
  NM_016315   GULP1         0.0007        2.04          apoptosis
  NM_006595   API5          0.0004        2.02          apoptosis
  Q01082 S    PTBN1         0.00005       4.52          cytoskeleton/motility
  NM_005909   MAP1B         0.002         3.01          cytoskeleton/motility
  P35749      MYH11         0.0005        2.88          cytoskeleton/motility
  Q13642      FHL1          0.002         2.59          cytoskeleton/motility
  Q9NYL9      TMOD3         0.0002        2.39          cytoskeleton/motility
  P35222      CTNNB1        0.005         2.04          cell adhesion receptors
  NM_006158   NEFL          0.0006        0.10          cytoskeleton/motility
  NM_004995   MMP14         0.003         3.96          protein turnover
  NM_013381   TRHDE         0.008         2.33          protein turnover
              LTBP1         0.003         0.50          protein kinase activity
  NM_000849   GSTM3         0.0002        7.99          metabolism
  NM_000850   GSTM4         0.005         2.36          metabolism
  P06733      ENO1          0.005         2.07          metabolism
  P08294      SOD3          0.0005        0.44          metabolism
  NM_004177   STX3A         0.0007        0.53          trafficking/targeting proteins
  Q9NZ08      ARTS-1        0.008         2.20          stress response proteins
  AF112465    OGN           0.003         3.05          membrane channels
  NM_000725   CACNB3        0.001         0.54          membrane channels
  L22548      COL18A1       0.002         0.51          membrane channels
              PTGIS         0.009         2.58          lipid biosynthesis

Partial list of genes from several functional categories differentially expressed in leiomyomas of African Americans as compared to Caucasians as illustrated in figure 1 and selected based on p ≤ 0.001 and 2-fold cutoff change (F. Change) as described in materials and methods. The complete list is provided as in Additional file [1](#S1){ref-type="supplementary-material"}.

![Hierarchical cluster analysis of differentially expressed genes in matched leiomyoma and myometrium from African Americans (AAL1, AAL2, AAL3, AAM1, AAM2, AAM3) and Caucasians (CL1, CL2, CL3, CM1, CM2, CM3) selected at P ≤ 0.01 followed by 2-fold cutoff change. Each column represents data from a single cohort with shades of red and green indicating up- or down-regulated genes according to the color scheme shown below. Genes represented by rows were clustered according to their similarities in pattern of expression in each tissue. The dendrogram at the top of the image displays similarity in gene expression among the cohorts, and relatedness of the arrays is denoted by distance to the node linking the arrays. The clustering divided the genes into five clusters designated as A to E.](1477-7827-5-34-1){#F1}

Gene expression using TaqMan LDA
--------------------------------

We used customized 384-well LDA cards to determine the expression of 15 genes in leiomyomas and myometrium, with each card containing two replicates of the target genes and GAPDH as a housekeeping gene (Fig. [2](#F2){ref-type="fig"}). Since these cards were also used to assess the expression of these genes in tissues reported in the accompanied manuscript \[[@B20]\] we first established the least variable housekeeping gene to use as a standard among these tissues. Using factory-loaded LDA cards representing 12 housekeeping genes GAPDH expression displayed the least variation among these tissues (data not shown). Based on these results we selected GAPDH as a housekeeping gene and along with 23 target genes for preparation of customized LDA for our study. The selection of the 23 genes was based on the result of the present and our previous microarray studies \[[@B6],[@B7],[@B19]\]. Figure [2](#F2){ref-type="fig"} show the level of expression of E2F1, RUNX3, EGR3, TBPIP, ECM2, ESM1, THBS1, GAS1, ADAM17, CST6, CST7, FBLN5, ICAM2, EDN1 and COL18, representing transcription factors, cell cycle and apoptosis regulators, matrix remodeling and cell adhesion signaling, respectively in matched leiomyoma and myometrium from African Americans and Caucasians. The level of expression of these genes varied significantly in leiomyoma and myometrium as well as tissues from African Americans as compared to Caucasians (Fig. [2](#F2){ref-type="fig"}; P \< 0.05), some displaying a similar pattern of expression observed with microarray.

![Bar graphs show the relative level of expression of 15 of the differentially expressed genes in paired myometrium (M) and leiomyomas (L) from Caucasians (C) and African Americans (AA) determined by realtime PCR low density array. Values on the y-axis represent an arbitrary unit derived from the mean expression of each gene independently with the mean value of myometrium from Caucasian set at 1 for each gene. The asterisks \* are statistically different from \*\* comparing paired myometrium and leiomyomas from African Americans and Caucasians with arrows pointing out the difference between the expression of these genes in leiomyoma and myometrium in each group. A probability level of P \< 0.05 was considered significant.](1477-7827-5-34-2){#F2}

Proteomic analysis of leiomyomas and myometrium
-----------------------------------------------

A representative of total protein isolated from a paired myometrium and leiomyoma, labeled with Cy3 or Cy5 respectively, and co-separated in 2D PAGE is shown in Figure [3A](#F3){ref-type="fig"}. Using image analysis 332 protein spots were identified and their density/volume determined with two spots (\#107 and \#192) later extracted for identification shown in graphic presentation (Fig. [3B](#F3){ref-type="fig"}). The average density of each protein spot in leiomyomas and myometrium was normalized against their density in one of the myometrium from a Caucasian patient. Of the 332 protein spots identified 28 and 31 spots were unique to leiomyomas and myometrium, respectively with the density/volume of 31 spots varied by at least 1.5 fold (12 were overexpressed and 19 underexpressed) in leiomyomas as compared to myometrium regardless of ethnicity. 109 protein spots identified in leiomyomas the average density/volume of 34 spots differed by at least 1.5 fold, of which 26 spots were overexpressed and 8 were underexpressed in African American as compared to Caucasians (Table [2](#T2){ref-type="table"}). Mass spectrometric analysis of 15 selected spots resulted in identification of 137 proteins. A database search against Swiss-Prot resulted in identification of several proteins and the results are summarized in Table [3](#T3){ref-type="table"}, with MS and MS/MS scores showing the reliability of identification. Among the content of these protein spots included several keratins, Annexin A1 and V, transgelin (SM22), galgizzarin (S100A11) and EF-hand domin-containing protein 2 (S100A12), vimentin, retinoic acid binding protein II, cofilin, several isoforms of 14-3-3 and mimecan. Transcripts corresponding to these proteins were also identified among differentially expressed genes in leiomyomas and myometrium of both ethnic groups (Table [3](#T3){ref-type="table"}).

###### 

Profile of protein spots detected in leiomyomas from Caucasians and African Americans

  **Tissue**      **Increased Intensity**   **Decreased Intensity**   **Not Changed**   **Not-Detected**
  --------------- ------------------------- ------------------------- ----------------- ------------------
  Fibroid-315C    31 (1.7--8.90 fold)       289 (1.5--48.80 fold)     \-\-\-\--         
  Fibroid-316C    42 (1.5--13.2 fold)       171 (1.5--46.00 fold)     61                55
  Fibroid-317C    129 (1.5--14.8 fold)      135 (1.5--128.7 fold)     3                 64
  Fibroid-344AA   180 (1.5--41.6 fold)      62 (1.5--37.70 fold)      7                 81
  Fibroid-353AA   81 (1.5--35.3 fold)       100 (1.5--86.80 fold)     33                118
  Fibroid-357AA   80 (1.5--14.1 fold)       65 (1.5--38.20 fold)      22                165

The number of protein spots detected in leiomyomas from Caucasians (315C, 316C and 317C) and African Americans (334AA, 353AA and 357AA) as compared to protein spots detected in myometrium of 315C used for normalization. Total number of spots detected in myometrium \#315 was 332. The column shows the number of spots whose intensity increased, decreased, not changed (± 1.5 fold), or not detected as compared to myometrium \#315C. The range of difference in protein spot intensity is shown as fold change as compared to their intensity in myometrium 315C.

###### 

List of protein spots and their contents identified by MS/MS in leiomyomas and myometrium

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Protein Spots**   **Description**                                           **Accession Number**   **Theoretical MW**   **Theoretical pI**   **Score**   **Match**   **Transcripts \***
  ------------------- --------------------------------------------------------- ---------------------- -------------------- -------------------- ----------- ----------- --------------------
  76                  Annexin A1                                                P04083                 38.6                 6.64                 361         10          \+

                      Aflatoxin B1 Aldehyde\                                    O43488                 39.6                 6.70                 359         11          \+
                      reductase 2                                                                                                                                        

                      Splice Isoform 1                                          P31942                 36.9                 6.37                 327         9           \+

                      Heterogeneous nuclear ribonucleoprotein H3                                                                                                         

                      PDZ and LIM domain protein 1                              O00151                 35.9                 6.55                 257         5           \+

                      PTD012 protein                                            Q6FI88                 35.1                 6.23                 217         7           \+

                      LIM and SH3 domain protein 1                              Q14847                 29.7                 6.61                 114         3           \+

  93                  CGI-150 protein                                           Q9Y3E8                 55.0                 8.89                 495         13          \+

                      Inorganic pyrophosphatase                                 Q9H2U2                 38.0                 7.07                 106         3           \+

  107                 Annexin V                                                 P08758                 35.8                 4.94                 619         23          \+

                      Mimecan                                                   P20774                 33.9                 5.46                 329         6           \+

                      Microtubule-associated protein RP/EB1                     Q15691                 29.9                 5.02                 180         4           \+

                      EF-hand domain-containing protein 2                       Q96C19                 26.7                 5.15                 155         3           \+

                      Tubulin-specific chaperone B                              Q99426                 27.3                 5.06                 132         3           \+

  126                 14-3-3ε                                                   Q04917                 28.1                 4.76                 339         8           \+

                      14-3-3τ                                                   P27348                 27.8                 4.68                 317         7           \+

                      14-3-3γ                                                   P61981                 28.2                 4.80                 231         8           \+

                      14-3-3β/α                                                 P31946                 28.0                 4.76                 170         6           \+

                      Annexin V                                                 P08758                 35.8                 4.94                 162         4           \+

                      Proteasome α5                                             P28066                 26.4                 4.74                 157         4           

                      Vimentin                                                  P08670                 53.5                 5.06                 124         3           \+

                      Acidic leucine-rich nuclear phosphoprotein 32A            P39687                 28.6                 3.99                 92          2           \+

  183                 α crystallin B chain                                      P02511                 20.2                 6.76                 489         28          \+

  187                 Transgelin (SM22)                                         Q5U0D2                 22.6                 8.87                 632         28          \+

  192                 Myosin regulatory light chain 2, smooth muscle isoforms   P24844                 19.7                 4.8                  333         15          \+

                      Myosin regulatory light chain 2, nonsarcomeric            P19105                 19.7                 4.67                 224         9           \+

  204                 Splice Isoform CFL2b of                                   Q9Y281                 18.7                 7.66                 263         10          \+

                      Cofilin, muscle isoforms                                                                                                                           \+

                      Cofilin, non-muscle isoforms                              P23528                 18.4                 8.26                 172         6           \+

                      Transgelin (SM22)                                         Q01995                 22.5                 8.88                 96          3           \+

  206                 Transgelin (SM22)                                         Q01995                 22.5                 8.88                 329         14          \+

                      Destrin alpha                                                                                                              309         17          \+

  209                 Actin-related protein 2/3                                 O15511                 16.2                 5.47                 245         14          \+

                      complex subunit 5                                                                                                                                  

  243                 Retinoic acid-binding protein II, cellular                P29373                 15.6                 5.43                 208         19          \+

                      14 kDa phosphohistidine phosphatase                       Q9NRX4                 13.8                 5.65                 105         3           \+

  303                 Calgizzarin (S100A11)                                     P31949                 11.7                 6.56                 164         10          \+

                      Cytochrome c oxidase polypeptide Vib                                                                                       64          4           \+

  324                 Ubiquitin                                                 P62988                 8.56                 6.56                 203         17          \+
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The identified proteins and their corresponding MASCOT scores obtained by 2D-PAGE separation combined with MALDI-TOFMS PMF and nano-HPLC-ESI-MS/MS peptide sequencing. Spot numbers corresponds to data in Fig. 3 with changes in their expression reported in Table 2. The corresponding transcripts (\*) of the proteins identified by microarray in leiomyomas and myometrium at p ≤ 0.05 and 2-fold cutoff are shown as + in the right hand side column. The Accession numbers, theoretical MW and pI are according to and calculated from Swiss-Prot.

![Two-dimensional gel electrophoresis of total protein isolated from leiomyoma and myometrium. Protein spots with differentiate expression are encircled and identified by a number. The spots were identified using MALDI-TOF and peptide matching. Figures B to E show the three-dimensional images with differential expression of two protein spots (\#107 and 192) in leiomyomas of African American (C and E) and Caucasians (B and D)](1477-7827-5-34-3){#F3}

Western blot analysis and immunohistochemical localization
----------------------------------------------------------

Western blot analysis indicated that leiomyoma and myometrium from both ethnic groups express 14-3-3β with a considerable variation among these tissues (Figs. [4](#F4){ref-type="fig"}). We were unable to detect mimecan immunoreactive protein in these tissue extracts by western blotting possibly because of the nature of the antibody for this application.

![Western blot analysis of 14-3-3β (30 Kd) and β-actin (control) in paired leiomyoma (L) and myometrium (M) from African Americans (Af. American) and Caucasians. The bar graph shows the relative expression (band density) of 14-3-3β in leiomyomas and myometrium in ethnic-dependent and independent manners. The asterisks \*\* are statistically different from \* (P \< 0.05).](1477-7827-5-34-4){#F4}

Immunohistochemically, 14-3-3β (Fig. [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}) and mimecan (Fig. [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}) were localized in leiomyoma and myometrial smooth muscle cells, connective tissue fibroblasts and vascular cells, with a considerable variability in their intensity among these cells within the same tissue (Figs. [5](#F5){ref-type="fig"}). Incubation of the tissue sections with normal rabbit and/or goat serum instead of the primary antibodies resulted in considerable reduction in staining intensity (Fig. [5E](#F5){ref-type="fig"} and [5F](#F5){ref-type="fig"}; the insert images show a higher magnification portion of these figures indicated by the arrows).

![Immunohistochemical localization of 14-3-3β (A and B) and mimecan (C and D) in myometrium (A and C) and leiomyomas (B and D) associated with leiomyoma and myometrial smooth muscle cells and cellular components of connective tissue and vasculature with inserts showing a higher magnification portion of these tissues. Incubation of tissue sections with non-immune rabbit (E) and goat (F) IgGs instead of primary antibodies during immunostaining, served as controls, reduced the staining intensity. Mag: X150; inserts = X265](1477-7827-5-34-5){#F5}

Discussion
==========

Using genomic and proteomic strategies the present study provided further insight into the molecular environments of leiomyoma and myometrium in Caucasians and African Americans. At genomic level 1470 genes or about 10% of the transcripts on the array were identified as differentially expressed in leiomyomas as compared to myometrium regardless of ethnicity. Of these genes 268 were identified as either over-expressed (177 genes) or under-expressed (91 genes) in leiomyomas of African Americans as compared to Caucasians. Hierarchical cluster analysis separated these genes into several clusters reflecting their tissue as well as ethnic-dependent and -independent association. However, the profile of some of the genes in these clusters displayed an area of relatedness between myometrium and leiomyomas within each ethnic group. This suggests that some of the differences in leiomyoma\'s gene expression might be attributed to differences in myometrial gene expression between the ethnic groups, as well as the differences in leiomyomas vs. myometrium. Functional analysis indicated that the majority of these genes serve as transcriptional, translational and signal transduction mediators, cell cycle regulation, ECM turnover, cell-cell communication and transport/metabolic activities.

At proteomic level we identified several proteins displaying both ethnic-dependent and -independent profiles, with 34, or 10% of total protein spots identified, displaying altered intensity in leiomyomas of African Americans as compared to Caucasians. Tandem mass spectrometry analysis of 15 selected protein spots revealed an array of proteins as part of their content (Table [2](#T2){ref-type="table"}) of which the transcripts of some of them, or their related proteins, were among the genes identified in myometrium and leiomyomas. Although the genomic and proteomic results of our study in part confirmed the previous reports involving leiomyomas and myometrium \[[@B8]-[@B10],[@B12],[@B13],[@B19],[@B23],[@B24]\], previous microarray analysis did not consider the influence of ethnicity as part of their comparative assessment. We recognize that low sample size is a limitation of our study, however validating the expression of a large number of transcripts simultaneously in the same samples by quantitative realtime PCR (low density array) and identification and confirmation of two proteins, mimecan (osteoglycin) and 14-3-3β in paired leiomyoma and myometrium compensated for this limitation.

Of the genes functionally relevant to processes that contribute to characteristic and pathogenesis of leiomyomas was the identification of several components of TGF-β system and their elevated expression in leiomyomas of African Americans as compared to Caucasians. Based on this and our previous studies we consider over-expression of TGF-β and TGF-β receptors in leiomyomas of African Americans result in further amplification of their signaling, targeted transcription factors and downstream genes expression, which are already altered in leiomyomas as compared to myometrium \[[@B7],[@B19],[@B22],[@B25]-[@B28]\]. In contrast, leiomyomas of African Americans expressed lower levels of LTBP-1, a member of fibrillin super-family that associates and stores TGF-β into the ECM. LTBPs consist of LTBP-1 to LTBP-4 \[[@B29]\] with LTBP-1 and -2 expression reported in leiomyomas \[[@B30],[@B31]\]. Commencing our study a recent report provided evidence for the expression of LTBP-1 and FBN-1 in leiomyomas of three different sizes with higher levels of expression in the medium-sized (3--5 cm) tumors compared with myometrium in the proliferative phase, while FBN-1 mRNA expression was size-independent \[[@B31]\]. Although the results suggested that ECM turnover in leiomyomas might be size-dependent, the larger tumors undergo significant alteration in their tissue structure, specifically at the center that must be taken into account during such comparative analysis. Our results that LTBP-1 is expressed at lower levels in leiomyomas of African Americans as compared to Caucasians suggest that TGF-β upon secretion and activation becomes readily available for binding rather than being stored into the ECM, a mechanism that regulates local availability of many growth factors and cytokines, including TGF-β.

Plasmin, integrins, thrombospondin-1 (TSP-1), mannose 6-phosphate, and decorin are known to activate TGF-β \[[@B32]-[@B34]\] and their differential expression suggests the presence of regulatory mechanism that control TGF-β action in leiomyoma where it regulates the expression of several genes involved in tissue fibrosis \[[@B19],[@B25]-[@B28],[@B35]\]. Additionally, we identified TCF8/ZB-1, a member of zinc finger transcription factors that include Smad interacting protein 1 (SIP1/ZEB-2), as differentially expressed gene in leiomyomas of African Americans. TCF8 through interaction with Smad and recruitment co-activator (p300) and co-repressor (CtBP), is involved in ER and TGF-β receptors signaling \[[@B35]-[@B37]\]. Leiomyomas express these and several other transcription factors that interact with TCF8 including Runx, CITED, EGR1, EGR3, E2F1, Nurr77, c-Myc, Max, and Mad, whose expression is validated in this and our previous study \[[@B7],[@B19]\]. These transcription factors regulate the expression of group of genes involved in cell cycle regulation, apoptosis, angiogenesis and inflammation mediated by the action of TGF-β receptor and ER activation \[[@B38]-[@B43]\]. Because leiomyomas grow more rapidly in African Americans as compared to other ethnic groups, altered expression of these genes regulated by TGF-β and ovarian steroids could influence the outcome of this process.

A balance between cell growth and apoptosis is critical in progression of tissue fibrosis and the expression of several genes functionally related to these categories, including Bcl-XL, Bad, Bax, p27Kip1, p57Kip2, Gas1, Gas7, CST6, CST7, caspases, etc., were identified in leiomyomas and myometrium. Differential expression of some of these genes in leiomyomas of African Americans most likely contributes toward their rapid growth as compared to other ethnic group. Local apoptotic and non-apoptotic cell-death also results in regulation of multiple genes involved in inflammation, angiogenesis, fibrogenesis and tissue turn over. Among these genes involved in these processes are collagens, versican, fibromodulin, syndecan 4, TSP-1, tenascin-C, osteonectin/SPARC and ECM2, endothelial cell specific molecule-1 (ESM-1), ICAM2, EDN1, FZD7, β1 catenin, CST6, CST7 as well as several member of integrins, MMPs, TIMPs and ADAMs \[[@B44]-[@B49]\] that are expressed in leiomyomas \[[@B7],[@B26],[@B27]\] with altered expression in African Americans. The identification of 14-3-3β and mimecan as differentially expressed genes in leiomyomas of African Americans is also of interest. 14-3-3s are regulatory proteins that bind to a variety of cellular targets, including Raf kinase, cell cycle-dependent phosphatase Cdc25, pro-apoptotic protein Bad and many others proteins and are considered to regulate hypertrophic scar formation through regulation of MMPs expression \[[@B50]-[@B52]\]. The ability of 14-3-3 proteins to bind and regulate various oncogenic gene products as well as various tumor suppressor gene products points to a potential role in cancer As such 14-3-3 has been shown to inhibit TSC1/TSC2 complex functions and overexpression of either TSC1 or TSC2 in Hela cells has been reported to increase the expression of various 14-3-3 isoforms \[[@B53]\] suggesting that deregulated expression of 14-3-3 and TSC can be associated with leiomyoma pathogenesis. Mimecan is a member of small leucine-rich proteoglycans family, which includes lumican, fibromodulin, decorin and biglycan, and has been implicated in collagen fibrillogenesis, cellular growth, and migration \[[@B54]-[@B56]\]. Mimecan is secreted and proteolytically cleaved by a serine protease to form the 25--30 kDa form found in association with ECM of connective tissue and considered to play a structural role by maintaining the tensile strength and hydrated nature of the tissue \[[@B55],[@B56]\]. Mimecan is expressed in mouse pituitary gland and in human anterior pituitary gland and Pit-1 is reported to activate the human mimecan promoter through Pit-1 response element sites \[[@B57]\]. As such mime can and 14-3-3 as well as other genes products in these categories may have a similar biological activity in leiomyoma pathogenesis, specifically in African Americans with more symptomatic tumors.

Because the ovarian steroids are critical to fibroid growth it is essential to assess their relationship with genomic and proteomic profiling presented here since the expression of some of these genes are the target of ovarian steroids regulatory functions. Since the tissues used in our study come from the early-mid secretary phase of the menstrual cycle it is possible to assume that both estrogen and progesterone-dependent and independent mechanism influence the expression of these genes. Additionally, we only identified the content of 15 of the protein spots isolated from the proteomic protein profiling as compared with a large number of genes identified by microarry. This limited our ability to assess any overlapping expression between genomic and proteomic results which determine whether different genes or proteins are regulated at different molecular level since some genes are regulated at transcription level, while others at protein level.

In conclusion, subjecting paired leiomyoma and myometrium from African Americans and Caucasians to genomic and proteomic analysis we identified a considerable similarity between their molecular environments with differences seen at the level rather than ethnic-specific expression of a number of genes. The area of relatedness among some of the gene clusters between myometrial and leiomyomas within each ethnic group suggests that some of the differences in leiomyoma\'s gene expression might be attributed to differences in myometrial gene expression between the ethnic groups, in addition to differences in leiomyomas vs. myometrium. Because many of the differentially expressed genes identified in these cohorts are know to regulate inflammatory response, angiogenesis, cell cycle, apoptosis and ECM matrix turnover, their products may account for rapid growth and associated symptoms in African Americans as compared to other ethnic groups.
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